StockUS listing USXENENASDAQHealthcareEarnings Deterioration

Xenon Pharmaceuticals Inc(XENE) Stock Analysis | Healthcare

USD --+0.00%
Reward37Moderate
Risk19Low
75%Data
Revenue down 100% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 3.98Bn
Reward Ratingⓘ37 Moderate reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ19 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on XENE to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Xenon Pharmaceuticals Inc?

, a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders.

AI Brief Pro

The brief on Xenon Pharmaceuticals Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Xenon Pharmaceuticals Inc?

, a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.98B.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (37)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.082
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
7296,707 shares
$17.8M
0
9-12months
465,302 shares
$2.9M
0